Exscientia vs Tempus

Tempus has a disclosed valuation of $8.1B, while Exscientia's valuation is not publicly available, making a direct size comparison difficult. Tempus employs 2500 people.

Tempus has raised more in total funding at $1.1B, compared to Exscientia's $500M — a gap of $550M. Combined, the two companies have completed 6 known funding rounds.

Tempus leads with an Awaira Score of 84/100, while Exscientia sits at 72/100. That 12-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

Exscientia was founded by Andrew Hopkins in 2012. Tempus was founded by Eric Lefkofsky in 2015. Visit each company's profile on Awaira for a full founder biography.

Exscientia: Exscientia is an AI-driven drug design company that uses automated design-make-test-analyse cycles to generate drug candidates with the goal of reducing the time and cost of small molecule drug discovery. The Oxford-originated company builds generative chemistry models and automated laboratory robotics that together create a closed-loop system for molecular design, synthesis, and assay testing, producing candidates in months rather than the years required by conventional medicinal chemistry programmes.\n\nThe company went public on NASDAQ under the ticker EXAI, having raised over $500 million in combined public and private funding from investors including Bristol-Myers Squibb, Celgene, SoftBank, and GT Healthcare Capital Partners. Exscientia has clinical-stage programmes in oncology and neuropsychiatry and reports being the first company to advance AI-designed drug candidates into human clinical trials. The company has multiple pharma partnerships including agreements with Bristol-Myers Squibb, Sanofi, and Evotec that provide milestone and royalty revenue.\n\nExscientia competes in the AI drug design space against Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics, and Insilico Medicine. The company differentiates through its integrated automated laboratory approach, which combines computational design with physical synthesis and testing in a single workflow rather than treating AI design as a separate step before conventional chemistry. Its public market position and disclosed clinical programmes provide transparency benchmarks against which the broader AI drug discovery sector is measured by investors and pharmaceutical partners. Tempus: Tempus is an AI-driven oncology and precision medicine company founded in 2015 that utilizes machine learning and data analysis to improve cancer treatment outcomes. The platform aggregates and analyzes vast datasets including clinical data, imaging, molecular information, and outcomes to identify personalized treatment strategies for cancer patients. Tempus's core technology uses artificial intelligence to match patient-specific tumor characteristics with optimal therapeutic options, enabling oncologists to make data-informed treatment decisions. The company operates primarily in the United States and serves hospitals, health systems, and oncology practices through its cloud-based platform. Its applications span multiple cancer types including lung, colorectal, breast, and ovarian cancers. Tempus has secured $1.3 billion in total funding and achieved a valuation of $8.1 billion, reflecting significant investor confidence in precision oncology. The company went public, transitioning from private to public markets. Tempus competes with other AI health platforms and precision medicine companies like Foundation Medicine and others focused on genomic analysis and treatment selection. The company's growth trajectory reflects expanding adoption of AI-driven oncology tools and increasing demand for personalized cancer treatment protocols. Its competitive positioning centers on its data infrastructure scale and machine learning capabilities applied to complex clinical decision-making. Tempus combines clinical, imaging, and molecular data through AI to provide real-time oncology treatment recommendations at scale across U.S. health systems.

Exscientia got there first, launching in 2012 — that's 3 years of extra runway. Tempus didn't arrive until 2015. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

Exscientia has about 100-500 employees; Tempus has about 2500. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Exscientia and Tempus compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.